Molecular Theranostics LLC
Cleveland, OH
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
- Physical address
- 7100 Euclid Ave Suite 152, Cleveland, OH 44103, USA
- Website
- mtheranostics.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Collagen Medical LLC | Boston, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Reveal Pharmaceuticals, Inc. | Cambridge, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Inlighta Biosciences L.L.C. | Marietta, GA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Cellsight Technologies, Inc. | San Francisco, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Mtti | West Chester, PA | 325413 In-Vitro Diagnostic Substance Manufacturing |
About the company
Molecular Theranostics LLC, a self-certified small disadvantaged business and Asian-Pacific American-owned limited liability company based in Cleveland, Ohio, develops targeted molecular imaging and therapeutic agents for cancer detection, diagnosis, and treatment as a federal grant recipient under National Institutes of Health programs. The company operates exclusively as a prime recipient on federal research grants; it holds no federal contracts, IDVs, or subcontracts in the source data.
Molecular Theranostics' capability portfolio centers on the design, synthesis, and optimization of targeted contrast agents and drug conjugates for oncology applications. The vendor's signature platform technology is MT218, a first-in-class targeted MRI contrast agent specific to extradomain-B fibronectin in tumor extracellular matrix, which has demonstrated safety in preclinical assessments and early clinical trials. Recent representative grant work includes a $528,259 award from the National Cancer Institute (CFDA 93.394, Cancer Detection and Diagnosis Research) running September 2026 through August 2031 to develop next-generation gadolinium- and manganese-based MRI contrast agents using PYCLEN chelating ligands that address safety concerns with current clinical agents; a National Institute of Dental and Craniofacial Research project grant awarded July 2024 through July 2026 to develop a peptide-targeted fluorescence probe for intraoperative imaging and precision surgical treatment of head and neck cancer; and an August 2023 National Cancer Institute award through July 2025 to develop peptide-drug conjugates for triple-negative breast cancer therapy. An earlier National Cancer Institute project grant (September 2022 through February 2026) focused on commercialization of MT218 for differential diagnosis of high-risk prostate cancer. All work is performed in Ohio. Molecular Theranostics' federal customer base is concentrated entirely within the Department of Health and Human Services: four awards from the National Cancer Institute, one from the National Institute of Dental and Craniofacial Research, and one from HHS broadly, accounting for six total awards with combined obligated dollars of $7.7 million across a six-year span (2015–2026). Activity is sporadic, with single awards in 2015, 2022, 2023, 2024, and 2026; the most recent award arrived in September 2026.
Quick answers
Is Molecular Theranostics LLC registered in SAM.gov?
Yes. Molecular Theranostics LLC's SAM.gov registration is active through July 5, 2027.
What is Molecular Theranostics LLC's CAGE code?
Molecular Theranostics LLC's CAGE code is 72M95, and its Unique Entity ID (UEI) is L1VLYM9HZNK3.
What is Molecular Theranostics LLC's most recent federal award?
Molecular Theranostics LLC's most recent federal grant award is Development of next-generation targeted MRI contrast agents - the objective of this research project is to develop… (R01CA297667), from National Cancer Institute (NIH), on September 1, 2026.
On GovTribe
See Molecular Theranostics LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors